E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update
January 17, 2023 08:00 ET | electroCore, Inc.
Record revenue of approximately $2.5 million for the three months ended December 31, 2022 and $8.5 million for full-year 2022Revenue growth of approximately 57% over full-year 2021Launched two new...
New Logo July 12, 2022.png
Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote
January 12, 2023 08:30 ET | Odyssey Health, Inc
Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga™
December 20, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic company, today announced the launch of a new wellness product offering called...
New Logo July 12, 2022.png
Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023
December 19, 2022 08:30 ET | Odyssey Health, Inc
Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing life-enhancing medical products, today...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Issuance of Two New U.S. Patents
December 07, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark...
New Logo July 12, 2022.png
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development
November 23, 2022 08:30 ET | Odyssey Health, Inc
Las Vegas, Nevada, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association
November 18, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has...
New Logo July 12, 2022.png
Odyssey Health, Inc. Schedules Annual Meeting of Stockholders
November 15, 2022 08:00 ET | Odyssey Health, Inc
Las Vegas, Nevada, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum
November 14, 2022 16:05 ET | electroCore, Inc.
ROCKAWAY, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan...
Aviv-Clinic Logo.png
Aviv Clinics and America’s Mighty Warriors Partner to Provide Life-Changing Treatments to Veterans Suffering from Concussion, Traumatic Brain Injury
November 11, 2022 09:12 ET | Aviv Clinics
ORLANDO, Fla., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Aviv Clinics, the global leader in the research and treatment of brain conditions, today announces a pledge of $1 million in in-kind treatments to...